Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 917-924

  Viganò, Alessandra ^a   Aldrovandi, Grace M ^b   Giacomet, Vania ^a   Merlo, Marzia ^a   Martelli, Laura ^a   Beretta, Silvia ^a   Luraschi, Paola ^a   Rombolà, Giuseppe ^c   Mora, Stefano ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; CHOLESTEROL; CREATININE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; PHOSPHORUS; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; BICARBONATE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; LIPID ANALYSIS; MALE; MICROALBUMINURIA; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; URINALYSIS; VIRUS LOAD;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; MALE; OXAZINES; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 30444446823     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. The New England Journal of Medicine 1998; 338:853-860.
2. Safrin S & Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors. AIDS 1998; 12:F51-F58.
4. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP & Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
5. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
6. Fontas E, Van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C & Reiss P; DAD Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? The Journal of Infectious Diseases 2004; 189:1056-1074.
7. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA & Touraine JL. A Syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
8. Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S & King SM. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003; 17:1319-1327.
9. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R & Zeichner S. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114:e235-e242.
10. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
11. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J & Cooper DA for Mitochondrial Toxicity Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. The Journal of the American Medical Association 2002; 288:207-215.
12. Martin A, Smith DE, Carr A, Ringland C, Amin J, Hemery S, Hoy J, Workman C, Doong N, Freund J & Cooper DA for Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a tnymidine analogue to abacavir: the MITOX extension study. AIDS 2004; 18:1029-1036.
13. Moyle G, Sabin C, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C & Reilly G & the Rave Study Group. A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. 12th Conference on Retrovirus and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 44LB.
14. Domingo P, Labarga P, Palacios R, Guerrero M F, Terron J A, Elias M J P, Santos J, Ruiz Camps M I, Libre JM, Moreno S and the RECOVER study group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18:1475-1478.
15. Hansen BR, Haugaard SB, Iversen J, Nielsen JO & Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scandinavian Journal of Infectious Diseases 2004; 36:244-253.
16. McComsey G, Bhumbra N, Ma JF, Rathore M & Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 2003; 111:e275-281.
17. Christensen B, Glueck C, Kwiterovich P, Degroot I, Chase G, Heiss G, Mowery R, Tamir I & Rifkind B. Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the prevalence study of the Lipid Research Clinics Program. Pediatric Research 1980; 14:194-202.
18. Pierrat A, Gravier E, Saunders C, Caira MV, Ait-Djafer Z, Legras B & Mallie JP. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney International 2003; 64:1925-1436.
19. Walton RJ & Bijvoet OL. Normogram for derivation of renal threshold phosphate concentration. The Lancet 1975; 2:309-310.
20. Nicholson JF & Pesce MA. References ranges for laboratory tests and procedures. In Nelson Textbook of Pediatrics. Edited by RE Behrman, RM Kliegman, HB Jenson. 2004; pp 2396-2427. Philadelphia: Saunders.
21. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis J PA, Holohan MK, Leavitt R, Boone G & Richman D. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. The New England Journal of Medicine 1998; 339:1261-1268.
22. Masquelier B, Neau D, Chene G, Larbere J, Birac V, Ragnaud J-M & Fleury HJA. Mechanism of virological failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. Journal of Acquired Immune Deficiency Syndromes 2001; 28:309-312.
23. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset L R, Fisher M, Vernazza P, Bernasconi E, Battegay M, Ledergerber, Gunthard H, Howe C, Weber & Perrin L for the Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. The Journal of Infectious Diseases 2002; 185:1251-1260.
24. Staszewski S, Morales-Ramirez J, Tashima KT, Rachilis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola D, Farina D, Manion D & Ruiz N M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. The New England Journal of Medicine 1999; 341:1865-1873.
25. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knober H, Riera M, Pedrol E, Force L, Libre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E & Gatell J M for the Nevirapine, Efavirenz and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. The New England Journal of Medicine 2003; 349:1036-1046.
26. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, Casamitijana R, Mallolas J & Gatell JM. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully-treated adults with lipodystropy. Clinical Infectious Diseases 2000; 31:1266-1273.
27. Negredo E, Ribalta J, Ferrè R, Salazar J, Rey-Joly C, Sirera G, Masana L & Clotet B. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18:819-821.
28. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V & Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regiments. Journal of Acquired Immune Deficiency Syndromes 2003; 33:544-546.
29. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D,Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM & Flynn PM. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. PACTG 382 Team. The New England Journal of Medicine 1999; 341:1925-1926.
30. Teglas JP, Quartier P, Treluyer JM, Burgard M, Gregoire V & Blanche S. Tolerance of efavirenz in children. AIDS 2001; 15:241-3.
31. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D & Salmon-Ceron D. Renal tubular dysfunction associated with tenofovir therapy. Report of 7 cases. Journal of Acquired Immune Deficiency Syndromes 2004, 35:269-273.
32. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V & Deray G. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18:1074-1076.
33. Gallant J, Parish M, Keruly J & Moore R. Decline in renal function associated with tenofovir DF compared with nucleoside reverse transcriptase inhibitor treatment. 12th Conference on Retrovirus and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 820.